Profile data is unavailable for this security.
About the company
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
- Revenue in INR (TTM)2.63bn
- Net income in INR253.14m
- Incorporated1988
- Employees799.00
- LocationSyncom Formulations (India) Ltd207, Saket NagarINDORE 452018IndiaIND
- Phone+91 7 312700458
- Fax+91 7 313046872
- Websitehttps://syncomformulations.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.45bn | 1.06k | 39.70 | -- | 17.23 | 1.70 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
Panacea Biotec Ltd | 5.52bn | -119.17m | 8.45bn | 1.09k | -- | -- | 16.43 | 1.53 | -1.89 | -1.89 | 89.86 | -- | -- | -- | -- | 5,046,990.00 | -- | 10.52 | -- | 18.65 | 56.88 | 50.87 | -2.21 | 27.34 | -- | -- | -- | 0.00 | -30.44 | -5.06 | -103.08 | -- | 21.89 | -- |
Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 9.09bn | 940.00 | 36.97 | -- | 34.60 | 4.12 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
Vimta Labs Ltd | 3.20bn | 413.41m | 10.73bn | 1.37k | 26.35 | -- | 14.22 | 3.35 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 11.29bn | 38.00 | 119.87 | 43.44 | 125.68 | 25.06 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
Lincoln Pharmaceuticals Ltd | 5.81bn | 933.05m | 11.37bn | 1.70k | 12.18 | 1.92 | 10.94 | 1.96 | 46.58 | 46.58 | 289.81 | 295.98 | 0.9017 | 3.78 | 3.90 | -- | 14.49 | 13.95 | 16.61 | 16.54 | 52.06 | 51.21 | 16.07 | 14.71 | 4.01 | 60.95 | 0.0018 | -- | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 11.45bn | 763.00 | 15.45 | 1.18 | 10.61 | 1.49 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
Kopran Ltd | 6.15bn | 509.56m | 11.46bn | 394.00 | 22.64 | 2.33 | 17.95 | 1.86 | 10.50 | 10.50 | 126.95 | 101.90 | 0.8824 | 2.99 | 3.28 | -- | 7.32 | 8.47 | 10.22 | 12.23 | 34.60 | 34.18 | 8.29 | 8.89 | 1.44 | 43.23 | 0.168 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
Beta Drugs Ltd | 2.56bn | 347.57m | 12.14bn | 315.00 | 34.94 | 8.55 | 26.53 | 4.74 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
Syncom Formulations (India) Ltd | 2.63bn | 253.14m | 12.41bn | 799.00 | 38.82 | 4.31 | 41.31 | 4.71 | 0.34 | 0.34 | 3.56 | 3.07 | 0.6732 | 7.42 | 2.95 | -- | 6.47 | 7.50 | 9.00 | 10.23 | 40.44 | 34.59 | 9.61 | 9.38 | 2.38 | 5.57 | 0.201 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
Zota Health Care Ltd | 1.68bn | -100.65m | 12.57bn | 338.00 | -- | -- | 177.08 | 7.49 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
Windlas Biotech Ltd | 6.31bn | 581.87m | 12.94bn | 1.05k | 22.27 | 2.88 | 18.07 | 2.05 | 27.94 | 27.94 | 302.99 | 216.33 | 1.09 | 5.79 | 4.99 | -- | 10.07 | -- | 13.50 | -- | 37.21 | -- | 9.22 | -- | 2.15 | 58.58 | 0.008 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
Ngl Fine Chem Ltd | 3.17bn | 380.04m | 14.37bn | 343.00 | 37.80 | -- | 28.89 | 4.53 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
Hester Biosciences Ltd | 3.05bn | 188.89m | 14.88bn | 693.00 | 70.29 | 5.10 | 38.82 | 4.89 | 24.89 | 24.89 | 392.38 | 343.01 | 0.4572 | 1.20 | 3.85 | -- | 3.18 | 6.15 | 4.00 | 7.69 | 68.52 | 68.83 | 6.95 | 12.83 | 1.31 | 1.84 | 0.4466 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
Holder | Shares | % Held |
---|---|---|
Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 6.61k | 0.00% |